Oral dapagliflozin reduced liver edema, necrosis, vascular hyperemia, and oxidative stress markers following ischemia-reperfusion injury in rats.
Does dapagliflozin reduce liver damage and oxidative stress in a rat model of liver ischemia-reperfusion injury?
Dapagliflozin demonstrates potential to lessen liver damage and oxidative stress in a rat model of ischemia-reperfusion injury.
orally. During surgery, liver ischemia was induced for 1 hr, followed by a 24-hr reperfusion period. The IR group exhibited elevated levels of alanine transaminase, aspartate transaminase, alkaline phosphatase, bilirubin, lactate dehydrogenase, and malondialdehyde compared to the control group. In contrast, the treatment group showed levels of these factors that were closer to those of the control group. While total protein, albumin, and total anti-oxidant capacity decreased in the IR group, this decline was less significant in the treatment group. Analysis of oxidative stress in liver tissue revealed that the treatment group had increased anti-oxidant capacity, and exhibited less oxidative stress compared to the IR group. Furthermore, dapagliflozin was found to reduce the degree of liver edema, necrosis, and vascular hyperemia following IR. Overall, dapagliflozin demonstrates the potential to lessen liver damage, enhance liver tissue regeneration, and mitigate the consequences associated with liver impairment.
Mahmoudi et al. (Thu,) conducted a other in Liver ischemia-reperfusion injury. Dapagliflozin vs. Control group (ischemia-reperfusion only) was evaluated on Liver damage markers, oxidative stress, and tissue injury. Oral dapagliflozin reduced liver edema, necrosis, vascular hyperemia, and oxidative stress markers following ischemia-reperfusion injury in rats.